The revolutionary PROPEL mini sinus stent, offered at New York-Presbyterian Weill Cornell, recently received expanded FDA approval to help improve results of sinus surgery for those suffering from chronic sinus conditions.
PROPEL mini sinus stent
The PROPEL mini sinus stent is a dissolvable, drug-releasing technology inserted at the end of sinus surgery. The spring-like device helps prop open the sinus airway after the surgery and gradually delivers anti-inflammatory medicine to the sinus lining, right where it’s needed. The stent is designed to dissolve within 45 days, so removal isn’t necessary.
PROPEL mini was previously approved by the FDA to treat ethmoid sinuses, which are located between the eyes. Recently, PROPEL mini received FDA approval to treat the sinuses located in the forehead area, allowing even more patients to potentially benefit from this technology. Patients who received PROPEL mini after sinus surgery needed fewer post-operative procedures and needed less oral steroids1,2.
“The PROPEL mini stent keeps the sinus open and gives us another tool to reduce the likelihood of the sinus becoming blocked again after surgery,” said the New York Otolaryngology Group . “This stent targets the sinuses with a sustained release of medicine to help the sinuses heal, then dissolves away. As a result of PROPEL mini’s new approval, even more patients can receive this important technology.”
After sinus surgery and placement of PROPEL mini, patients may breathe easier and ultimately find sinus relief.
About Chronic Sinus Disease
Chronic sinus disease is a condition in which sinuses become swollen and inflamed, leading to difficulty breathing, facial pain, headache and loss of sense of smell and taste. The condition is often misdiagnosed as allergies or a “never ending cold” and greatly impacts a person’s quality of life.
Chronic sinusitis is prevalent in the NYC area. “Propel provides a way to treat the sinus not only immediately after surgery but also continues to treat post operatively”
1 Han JK, Marple BF, Smith TL et al. Int Forum Allergy Rhinol. 2012; 2:271-279.
2 PROGRESS Study data as outlined in PROPEL mini Instructions For Use.
The PROPEL sinus implant is intended for use following ethmoid sinus surgery to maintain patency. PROPEL mini is intended for use following ethmoid or frontal sinus surgery to maintain patency. The implants are intended for use in patients ≥18 years of age. Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females has not been studied. Risks may include pain/pressure, displacement of implant, and possible side effects of intranasal MF. The most common adverse events in clinical studies were sinusitis, headache, epistaxis and bronchitis. For complete prescribing information see IFU at www.PROPELOPENS.com. Rx only.
PROPEL is a trademark and registered trademark of Intersect ENT, Inc.
Frequently Asked Questions
The PROPEL mini sinus stent is a dissolvable, drug-releasing device inserted at the end of sinus surgery. It props open the sinus airway and gradually delivers anti-inflammatory medicine directly to the sinus lining to aid healing. The stent dissolves within 45 days, eliminating the need for removal.
The PROPEL mini sinus stent recently received expanded FDA approval to treat not only the ethmoid sinuses between the eyes but also the frontal sinuses located in the forehead area. This expansion allows more patients with chronic sinus conditions to benefit from the technology.
Patients who receive the PROPEL mini stent after sinus surgery typically experience fewer post-operative procedures and require less oral steroids. The stent helps keep the sinus open and delivers sustained anti-inflammatory medication, promoting better healing and reducing the chance of sinus blockage.
The PROPEL mini sinus stent is intended for patients aged 18 and older undergoing ethmoid or frontal sinus surgery. It is not suitable for individuals with intolerance to mometasone furoate or hypersensitivity to bioabsorbable polymers. Safety in pregnant or nursing women has not been established.
Potential risks include pain or pressure, displacement of the implant, and side effects related to intranasal mometasone furoate such as sinusitis, headache, epistaxis, and bronchitis. Patients should consult their physician for complete safety information.
Chronic sinus disease causes swollen and inflamed sinuses leading to breathing difficulties, facial pain, headaches, and loss of smell or taste. PROPEL mini helps by maintaining sinus openness and delivering anti-inflammatory medication post-surgery, improving healing and symptom relief.
No, the PROPEL mini sinus stent is designed to dissolve on its own within approximately 45 days after placement, so patients do not require a separate procedure for removal.